Comparison of gene expression profiling between lung fibrotic and emphysematous tissues sampled from patients with combined pulmonary fibrosis and emphysema
© Hanaoka et al.; licensee BioMed Central Ltd. 2012
Received: 25 May 2012
Accepted: 11 September 2012
Published: 1 October 2012
Combined pulmonary fibrosis and emphysema (CPFE) is characterized by both emphysema of the upper zone and diffuse parenchymal lung disease with fibrosis of the lower zone of the lung on chest computed tomography. The aim of this study was to investigate the mechanism of CPFE regarding gene expressions by comparing the results of microarray sequences between fibrotic and emphysematous lesions in the lungs of CPFE patients.
The expression profiles of the fibrotic and emphysematous lesions were remarkably different in terms of function. Genes related to the immune system, structural constituents of the cytoskeleton, and cellular adhesion were overexpressed in fibrotic lesions, while genes associated with the cellular fraction, cell membrane structures, vascular growth and biology, second-messenger-mediated signaling, and lung development (all processes that contribute to the destruction and repair of cells, vessels, and the lung) were overexpressed in emphysematous lesions.
The differences in gene expression were detected in fibrotic and emphysematous lesions in CPFE patients. We propose that the development of coexisting fibrotic and emphysematous lesions in CPFE is implemented by these different patterns of gene expressions.
KeywordsEmphysematous lesion Cellular fraction Fibrotic lesion Gene expression profiles Immune system Lung
One of the most demonstrably clinical features of combined pulmonary fibrosis and emphysema is that emphysema of the upper zones and diffuse parenchymal lung disease with fibrosis of the lower zones of the lungs are both presented on chest computed tomography. The distinctive features of CPFE include cigarette smoking, severe dyspnea, hypoxemia at exercise, subnormal spirometry findings, and severely impaired lung diffusion capacity[1, 2]. Severe pulmonary hypertension is frequently observed in CPFE, and is thought to determine its prognosis[1, 3]. The substantial pathogenesis of CPFE is still unresolved because CPFE is not just one identical phenotype of either idiopathic pulmonary fibrosis (IPF) or emphysema[1, 2]. Genetic factors have been shown to play significant roles in the development of IPF. Fibrotic lung specimens from patients with IPF exhibited misexpressions of genes encoding proteins probably involved in the metabolism of the extracellular matrix (ECM), chemokines, and tissue remodeling. Genetic factors are also believed to be associated with the pathogenesis of emphysema. Lung tissues from patients with severe emphysema displayed irregular expression of genes involved in inflammation, the ECM, cytokines, chemokines, apoptosis, and stress responses.
We hypothesized that coexistent fibrosis and emphysema are programmed by differential gene expressions in the corresponding lesions in the lungs of smokers susceptible to CPFE. Given the importance of genetic susceptibility in understanding the etiology and pathogenesis of CPFE, we performed the whole-genome microarray to sequence the gene expression profiling on fibrotic and emphysematous tissues sampled from three patients with CPFE to identify genes distinguishably expressed in fibrotic lesions and emphysematous lesions in lung tissues of patients with CPFE.
The data reported in this paper have been deposited in the Gene Expression Omnibus database [GEO:GSE38934].
Summary of t test results, volcano plot and hierarchical clustering analysis
Gene functional classification for fibrotic lesions in CPFE
Gene functional classification for emphysematous lesions in CPFE
The present study demonstrates in patients with CPFE in which pulmonary fibrosis and emphysema coexisted that the genes overexpressed in the fibrotic lesions were functionally different from those overexpressed in the emphysematous lesions. The genes overexpressed in the fibrotic lesions were annotated as contributing to functions involving immunoglobulin, the structural constituents of the cytoskeleton, and cellular adhesion – biological functions that are related to the pathophysiology of fibrosis. The set of genes overexpressed in the emphysematous lesions were annotated as associated with cell membrane structures, vascular growth and biology, second-messenger-mediated signaling, and lung development – all processes that contribute to the destruction and repair of cells, vessels, and the lung. These annotation-based clusters suggest that functionally different genes expressed in susceptible fields of the lungs eventually contribute to the formation of either fibrosis or emphysema, depending on the pattern of gene expression in that field.
The major finding of the present investigation is that genes belonging to the clusters enriched for immunoglobulin-like molecules, the immunoglobulin constant region, and the immunoglobulin variable region were markedly expressed in the fibrotic lesions. The roles of autoimmunity in interstitial lung diseases (fibrosis in pathology) associated with connective tissue disorders such as systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis are well established. Autoimmunity has been demonstrated to be one of the mechanisms of alveolar injury responsible for IPF[6, 7]; the presence of autoantibodies in the sera of patients with IPF has been demonstrated elsewhere[8, 9]. Additionally, the initial hypothesis for the mechanism of pulmonary fibrosis was that pulmonary inflammation was a prominent and necessary feature of the fibrotic process. Those genes involved with immunoglobulin were probably expressed by the inflammatory cells in the infiltrates that were clearly presented in the fibrotic tissues. However, to date no candidate genes related to immunoglobulin-like molecules or members of the immunity system annotation cluster have been reported to be associated with lung fibrosis either in case–control association studies[11, 12] or in studies based on human genome oligonucleotide microarrays. Our observations provide the first evidence of a positive association of the immune system and pulmonary fibrosis at the genetic level. This major finding further supports the inflammation hypothesis of pulmonary fibrosis[10, 14].
Different from other findings in which the results of gene expression in pulmonary fibrosis were resulted from the comparisons of the gene expression datasets between fibrous tissues and healthy lung tissues or hypersensitivity pneumonitis lung tissues, we found that gene members of the structural constituent of cytoskeleton (keratin, claudin, dystonin) annotation cluster were overexpressed in CPFE fibrotic lesions versus emphysematous lesions. This observation provides genetic evidence in support of the latest mechanism of pulmonary fibrosis, which postulates that the losses of epithelial cells, endothelial cells, and alveolar–capillary barrier basement membrane integrity contribute to the pathogenesis of pulmonary fibrosis. Furthermore, we identified overexpression of the gene members of the cell adhesion annotation cluster in the fibrosis lesions of CPFE. Previously, cell adhesion molecules were shown to be expressed in the lungs of patients with IPF. Cell–cell and cell–ECM interactions are critical for the pathogenesis of pulmonary fibrosis. One of the essential mechanisms by which cells interact with the microenvironment is through the expression of cell adhesion molecules. Inflammatory cells may adhere to and injure lung parenchymal cells through binding to intercellular adhesion molecule 1. After initial injury, the abnormalities in interepithelial adhesion interactions, the interactions of ECM molecules with both epithelial cells and fibroblasts, and the disordered healing process eventually result in fibrosis.
Regarding the genes expressed in emphysematous lesions in CPFE, our results showed that the genes involved in cellular and membrane fractions, genes encoding proteins in membranes, genes related to blood vessel size, development, and angiogenesis, and genes related to second-messenger-mediated signaling were overexpressed versus fibrotic lesions of CPFE. We propose that the overexpression of genes with functions contributing to the cellular fraction and membrane structure may lead to the injury of pulmonary alveoli to cause emphysema. In addition, our observation of the overexpressed genes regulating blood vessel size, development, and angiogenesis in the emphysematous lesions in CPFE may explain the genetic susceptibility to high prevalence (up to 47%) of pulmonary hypertension in CPFE. We suggest that the overexpression of these vascular biology-related genes orchestrates the development and progression of pulmonary hypertension in CPFE. This hypertension may be a clinical characteristic that distinguishes CPFE from severe emphysema without fibrosis; the latter has a lower frequency of pulmonary hypertension than CPFE and expresses downregulated endothelium-related genes.
The main limitation of the present study is the very small sample size, with only three patients with CPFE, which occurred because lung tissue specimens were only occasionally available following invasive operations for other diseases; for example, lung cancer. Further study with a larger sample size is necessary to confirm our observations. Nevertheless, we believe that the present results motivate a new direction for understanding the coexistence of fibrosis and emphysema in CPFE.
In summary, we have demonstrated that gene expression differs between fibrotic and emphysematous lesions in CPFE. In the fibrotic lesions, genes associated with the immune system are highly expressed, while genes related to the cellular fraction, membrane biology, and vascular biology are highly expressed in emphysematous lesions. We propose that the development of coexistent fibrotic and emphysematous lesions in CPFE is implemented by these different patterns of gene expression.
Patients and specimens
According to the characteristics of CPFE addressed by Cottin and colleagues, six patients were selected for the current study. All six patients were originally diagnosed with lung cancer and high-resolution computed tomography showed not only the cancerous lesions but also emphysematous lesions in the upper zones and fibrotic lesions in the lower zones. The fibrotic and emphysematous lesions were located within the resected lobes. Further pulmonary function tests also indicated that impairment of carbon monoxide diffusing capacity and subnormal spirometry were present in these patients. CPFE was also diagnosed for these patients. Lung lobectomy was thought to be the optimal treatment for the lung cancer after consulting with chest surgeons. Specimens of fibrotic lesions and emphysematous lesions in lung tissues were sampled from the resected lobes of the six patients. Immediately after the lobectomy, the lung tissues with fibrosis and emphysema were separated from the resected lobes, and the lung tissue adjacent to each specimen was cut for histological confirmation of the absence of cancerous cells. The pathological types of fibrosis and emphysema were examined and confirmed after H & E staining by a pathologist who was blinded to the purpose of the study. This study was approved by the Ethics Committee of Shinshu University School of Medicine, and written informed consent was obtained from all patients.
Lung tissue specimens were immediately frozen in dry ice and stored at −80°C. RNA was extracted from the lung tissues using TRIzol Reagent (Life Technologies, Rockville, MD, USA) according to the manufacturer’s protocol. RNA for microarray analysis was purified using the RNeasy MinElute Cleanup Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s instructions. RNA quality was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
GeneChip expression preprocessing
In accordance with the standard Affymetrix protocol from the GeneChip Expression Analysis Technical Manual Revision 5, 2 μg total RNA was processed, biotinylated, fragmented, and hybridized to the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA). The Human Genome U133 Plus 2.0 chips consist of 54,765 probe sets and provide comprehensive coverage of the transcribed human genome on a single array, allowing the analysis of more than 47,000 transcripts and variants, including 38,500 well-characterized human genes plus approximately 6,500 new genes. Immediately following hybridization, the probe array underwent an automated washing and staining protocol on the Affymetrix Fluidics Station 450. The prepared GeneChips were then scanned using the Affymetrix GeneChip Scanner 3000. Each probe array was scanned twice and the software calculated an average of the two images, defined the probe cells, and computed the intensity for each cell. The double scan improved assay sensitivity and reduced background noise. Each complete probe array image was stored in a separate data file.
The scanned images were analysed with GeneChip Operating Software version 1.4 (Affymetrix 690036) and Microarray Suite version 5.0 (Affymetrix). The advantages of the Microarray Suite include the associated P values indicating statistical significance for detection and change calls, the confidence limits being associated with expression change values, and the negative expression values being eliminated. The profiling dataset from the emphysematous lesions was used as background when extracting the differentially expressed genes in the fibrotic lesions, and the data from the fibrotic lesions were used as background when extracting the differentially expressed genes in the emphysematous lesions. The trimmed mean target intensity of each array was set to 500. Differentially expressed genes were extracted using DNA Microarray Viewer (Kurabo, Osaka, Japan).
All microarray data of the individual lung tissue of the six specimens are freely available through the Gene Expression Omnibus repository [GEO:GSE38934].
The paired t test was performed for comparison of the detected signals between fibrotic and emphysematous lesions on the microarray data. The volcano plot was derived from the summary results of the paired t test to represent the point of intersection of fold-change (emphysema vs. fibrosis) relative to P value (emphysema vs. fibrosis). Clustering analysis was then carried out with log-transformed average signals of both fibrotic and emphysematous lesions on the microarray data and the heat map was built (Avadis 4.3; Strand Scientific Intelligence, San Francisco, CA, USA), according to the result of the hierarchical clustering analysis.
The SLR algorithm measures the magnitude and direction of the change between transcript levels of the experimental and background chips. A SLR of 1 represents a twofold increase in the abundance of an mRNA, and a value of −1 represents a twofold reduction in transcript expression. In the present analysis, we extracted genes with SLR >1 and SLR <1 for the fibrotic/emphysematous and emphysematous/fibrotic ratios, respectively. We then systematically annotated the large list of genes according to their biological functions using bioinformatics resources from the Database for Annotation, Visualization and Integrated Discovery, which provides the ability to explore and view functionally related genes together, as a unit, to concentrate on the large biological network rather than at the level of an individual gene. Condensing large gene lists into biologically meaningful modules greatly improves the ability to assimilate large amounts of information and thus switches functional annotation analysis from a gene-centric analysis to a biological module-centric analysis. Since an enrichment score of 1.3 is equivalent to 0.05 on the nonlog scale, we focused on gene clusters with scores ≥1.3 to address genes hypothetically involved in the phenotypes of the examined tissues.
Combined pulmonary fibrosis and emphysema
- H & E:
Hematoxylin and eosin
Idiopathic pulmonary fibrosis
Signal log ratio.
This study was partly supported by a grant to the Respiratory Failure Research Group from the Ministry of Health, Labor, and Welfare, Japan.
- Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF: Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005, 26: 586-593. 10.1183/09031936.05.00021005.View ArticlePubMedGoogle Scholar
- Kitaguchi Y, Fujimoto K, Hanaoka M, Kawakami S, Honda T, Kubo K: Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology. 2010, 15: 265-271. 10.1111/j.1440-1843.2009.01676.x.View ArticlePubMedGoogle Scholar
- Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, Barrientos E, Gaxiola M, Navarro C, Selman M: Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009, 136: 10-15. 10.1378/chest.08-2306.View ArticlePubMedGoogle Scholar
- Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, Kim DS, Kaminski N: Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009, 180: 167-175. 10.1164/rccm.200810-1596OC.PubMed CentralView ArticlePubMedGoogle Scholar
- Spira A, Beane J, Pinto-Plata V, Kadar A, Liu G, Shah V, Celli B, Brody JS: Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol. 2004, 31: 601-610. 10.1165/rcmb.2004-0273OC.View ArticlePubMedGoogle Scholar
- Jindal SK, Agarwal R: Autoimmunity and interstitial lung disease. Curr Opin Pulm Med. 2005, 11: 438-446. 10.1097/01.mcp.0000170522.71497.61.View ArticlePubMedGoogle Scholar
- Nicholson AG, Colby TV, Wells AU: Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis. 2002, 19: 10-17.PubMedGoogle Scholar
- Okayasu K, Ohtani Y, Takemura T, Uchibori K, Tamaoka M, Furuiye M, Miyazaki Y, Inase N, Yoshizawa Y: Nonspecific interstitial pneumonia (NSIP) associated with anti-KS antibody: differentiation from idiopathic NSIP. Intern Med. 2009, 48: 1301-1306. 10.2169/internalmedicine.48.2207.View ArticlePubMedGoogle Scholar
- Kakugawa T, Yokota S, Mukae H, Kubota H, Sakamoto N, Mizunoe S, Matsuoka Y, Kadota J, Fujii N, Nagata K, Kohno S: High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis. BMC Pulm Med. 2008, 8: 23-29. 10.1186/1471-2466-8-23.PubMed CentralView ArticlePubMedGoogle Scholar
- Strieter RM: Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002, 165: 1206-1207. 10.1164/rccm.2202055.View ArticlePubMedGoogle Scholar
- Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, Taniguchi H, Kubo M, Kamatani N, Nakamura Y: A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet. 2008, 45: 654-656. 10.1136/jmg.2008.057356.View ArticlePubMedGoogle Scholar
- Selman M, Lin HM, Montano M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, Lang CM, Pardo A, Phelps DS, Floros J: Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet. 2003, 113: 542-550. 10.1007/s00439-003-1015-4.View ArticlePubMedGoogle Scholar
- Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, McElvania-Tekippe E, Berman KG, Speer MC, Sporn TA, Brown KK, Schwarz MI, Schwartz DA: Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med. 2007, 175: 45-54.PubMed CentralView ArticlePubMedGoogle Scholar
- Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001, 134: 136-151.View ArticlePubMedGoogle Scholar
- Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, Aziz N, Kaminski N, Zlotnik A: Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006, 173: 188-198.PubMed CentralView ArticlePubMedGoogle Scholar
- Strieter RM, Mehrad B: New mechanisms of pulmonary fibrosis. Chest. 2009, 136: 1364-1370. 10.1378/chest.09-0510.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakao A, Hasegawa Y, Tsuchiya Y, Shimokata K: Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis. Chest. 1995, 108: 233-239. 10.1378/chest.108.1.233.View ArticlePubMedGoogle Scholar
- Paine R, Ward PA: Cell adhesion molecules and pulmonary fibrosis. Am J Med. 1999, 107: 268-279. 10.1016/S0002-9343(99)00226-0.View ArticlePubMedGoogle Scholar
- GeneChip Expression Analysis Technical Manual.http://jaxservices.jax.org/Affymetrix_Gene_expression_manual_430.pdf.
- GeneChip® Human Genome U133 Arrays.http://media.affymetrix.com/support/technical/datasheets/hgu133arrays_datasheet.pdf.
- Microarray Suite Version 5.0.http://www.biologie.ens.fr/lgmgml/Mito/mas5.pdf.
- Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4: 44-57.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.